Speaker Profile
Ph.D., American Cancer Society Professor of Genome Sciences and of Medical Genetics, U. of Washington School of Medicine
Biography
Mary-Claire King is a pioneering human geneticist best known for proving that breast and ovarian cancer can be inherited. In 1990, Dr. King and her team discovered the BRCA1 gene, which is responsible for a significant proportion of inherited breast and ovarian cancer cases. The finding came after roughly 17 years of research against prevailing scientific opinion, and it transformed cancer diagnosis, risk assessment, drug development, and prevention. Earlier, her doctoral work demonstrated through comparative protein analysis that chimpanzees and humans are 99 percent genetically identical. She also pioneered the use of DNA sequencing for human rights investigations, applying it to identify kidnapped children in Argentina and cases of human rights violations on six continents. Her current work spans inherited breast, ovarian, and prostate cancer; schizophrenia; and severe inherited disorders in children. She is a member of the National Academy of Sciences and the National Academy of Medicine.
Session Abstract – PMWC 2027 Silicon Valley
Track Chair:
Victor Velculescu, Johns Hopkins
PMWC Award Ceremony
• Rebecca Fitzgerald, University of Cambridge (Luminary)
• Mary-Claire King, University of Washington (Pioneer)
• Nickolas Papadopoulos, Johns Hopkins (Pioneer)
Featured Speakers
• Mary-Claire King, University of Washington
• Rebecca Fitzgerald, University of Cambridge
• Nickolas Papadopoulos, Johns Hopkins
• Victor Velculescu, Johns Hopkins
• Phil Castle, NIH
• Elad Ziv, UCSF
• Ash Alizadeh, Stanford
• Hamed Amini, Hepta
• Becky Taub, Madrigal Pharmaceuticals
• Trevor Pugh, University of Toronto
• Doga Gulhan, Harvard
• Pranav Rajpurkar, Harvard
• Chris Douville, Johns Hopkins
• Sylvia Katina Plevritis, UCSF
In Precision Medicine, Almost All Diseases Are Genetically Rare
A genetics-first keynote framing risk, prevention, and actionability.
The Reckoning
What the first wave of early detection got right and wrong.
The End of One Size Fits All
Risk-stratified screening, high-risk populations, and single-cancer tests.
Treating Disease at the Earliest Stage
Where detection and therapeutic interception begin to converge.
Pre-Cancer Detection & the Liver Disease Frontier
cfDNA and clinical action across the liver-disease-to-cancer continuum.
AI Across Multimodal Signals
Fragmentomics, methylation, imaging, pathology, and integration: hype versus real science.
PMWC Hall of Impact
Previous Speakers Include
Nobel laureates, technology founders, regulators, CEOs and scientific pioneers who have taken the PMWC stage.
